
Amgen Inc's new monoclonal antibody Prolia (denosumab) is the first "biologic therapy" approved by the FDA for the treatment of osteoporosis in menopausal women.

Amgen Inc's new monoclonal antibody Prolia (denosumab) is the first "biologic therapy" approved by the FDA for the treatment of osteoporosis in menopausal women.

Published: August 17th 2010 | Updated: